In recent years, the field of artificial intelligence technology has been attracting attention, on the one hand, it is true that artificial intelligence technology has unique advantages, its strong learning ability and intelligent response ability is quite welcome, such as the famous Go event – AlphaGo defeated the world’s No. 1 Go player Ke Jie; on the other hand, artificial intelligence technology is maturing and has made big breakthroughs in many aspects, artificial intelligence technology has blossomed in the service, financial, manufacturing and other industries, and the field of biomedicine has also ushered in the east wind of artificial intelligence to awaken the green and lush life.
Artificial intelligence biotechnology, covering the whole biomedical field
The application of artificial intelligence technology in the field of biomedicine covers from the source of new drug development to biopharmaceuticals and even clinical experiments. In the past, many tests and diagnoses are based on microscopic observation and doctors’ clinical experience, but in front of artificial intelligence, all doctors may be “newcomers”. According to reports, a meeting in Changsha, artificial intelligence technology and 200 of the country’s top doctors PK, the results of artificial intelligence judgment correct rate of 100%, more amazing is the time required less than 5 seconds, which is any famous doctor can not do. In fact, an artificial intelligence system has learned 80 million cases, so “full of experience”, which is a doctor can not do in a lifetime.
Artificial intelligence biotechnology, revolutionizing the face of biomedicine
Clinical trials are the landing point of biopharmaceuticals, while new drug development is the leader of biopharmaceuticals. New drug development is the top priority for the biopharmaceutical field, but new drugs, in addition to their relatively closed nature, themselves lack a large amount of learning resources to support the use of AI biotechnology. Admittedly, AI biotechnology still has a difficult journey to take to revolutionize the biopharmaceutical field, but there are already companies at home and abroad that have taken steps forward.
Since 2017, international pharmaceutical giants have deployed their own AI systems for improving the efficiency of new drug development, such as Merck, Novatis, Roche, Pfizer, Johnson & Johnsone, etc. Technology service platforms such as Great Bay Bio’s Klone 4.0 combine AI with biopharmaceuticals to make cell line development easier and more efficient.
As we all know, new drug development has always been a long-cycle work. The spring breeze of AI biotechnology allows new drug development to change from traditional labor-intensive to intelligent technology, which can create unlimited possibilities in a limited cycle.
Technology is the first productive force, and as the application of AI technology becomes more and more mature, the biopharmaceutical field ushers in more than just a windfall, it is likely to be an ecological innovation in the entire industry sector. From a macroscopic point of view, it can be applied to almost the entire industry chain from new drug research and development, drug production, clinical trials, etc.; from a microscopic point of view, the use of artificial intelligence technology in one step of new drug research and development alone, the entire new drug research and development efficiency may obtain exponential growth.